Vertex Pharmaceuticals Incorporated (VRTX)
USD 451.61
(-4.85%)
USD 451.61
(-4.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.61 Billion USD | 8.96% |
| 2022 | 3.32 Billion USD | 41.84% |
| 2021 | 2.34 Billion USD | -13.63% |
| 2020 | 2.71 Billion USD | 130.43% |
| 2019 | 1.17 Billion USD | -43.88% |
| 2018 | 2.09 Billion USD | 695.83% |
| 2017 | 263.48 Million USD | 335.14% |
| 2016 | -112.05 Million USD | 79.92% |
| 2015 | -558.11 Million USD | 24.43% |
| 2014 | -738.55 Million USD | -65.96% |
| 2013 | -445.02 Million USD | -315.79% |
| 2012 | -107.03 Million USD | -461.91% |
| 2011 | 29.57 Million USD | 103.92% |
| 2010 | -754.62 Million USD | -17.62% |
| 2009 | -641.57 Million USD | -39.52% |
| 2008 | -459.85 Million USD | -17.53% |
| 2007 | -391.27 Million USD | -89.12% |
| 2006 | -206.89 Million USD | -1.71% |
| 2005 | -203.41 Million USD | -22.36% |
| 2004 | -166.24 Million USD | 15.51% |
| 2003 | -196.76 Million USD | -81.15% |
| 2002 | -108.62 Million USD | -64.0% |
| 2001 | -66.23 Million USD | -67.01% |
| 2000 | -39.65 Million USD | 3.27% |
| 1999 | -41 Million USD | -23.87% |
| 1998 | -33.1 Million USD | -67.17% |
| 1997 | -19.8 Million USD | 50.5% |
| 1996 | -40 Million USD | -86.05% |
| 1995 | -21.5 Million USD | -22.16% |
| 1994 | -17.6 Million USD | -980.0% |
| 1993 | 2 Million USD | 123.53% |
| 1992 | -8.5 Million USD | -66.67% |
| 1991 | -5.1 Million USD | -18.6% |
| 1990 | -4.3 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.09 Billion USD | 13.5% |
| 2024 Q3 | 1.04 Billion USD | 129.09% |
| 2024 Q2 | -3.59 Billion USD | -426.81% |
| 2023 FY | 3.61 Billion USD | 8.96% |
| 2023 Q1 | 699.8 Million USD | -14.54% |
| 2023 Q2 | 915.7 Million USD | 30.85% |
| 2023 Q4 | 968.8 Million USD | -6.42% |
| 2023 Q3 | 1.03 Billion USD | 13.06% |
| 2022 Q2 | 810.5 Million USD | 6.35% |
| 2022 FY | 3.32 Billion USD | 41.84% |
| 2022 Q4 | 818.9 Million USD | -11.99% |
| 2022 Q1 | 762.1 Million USD | -1.04% |
| 2022 Q3 | 930.5 Million USD | 14.81% |
| 2021 Q3 | 851.92 Million USD | 1172.98% |
| 2021 FY | 2.34 Billion USD | -13.63% |
| 2021 Q1 | 653.13 Million USD | 8.1% |
| 2021 Q4 | 770.1 Million USD | -9.61% |
| 2021 Q2 | 66.92 Million USD | -89.75% |
| 2020 Q2 | 837.27 Million USD | 38.91% |
| 2020 Q1 | 602.75 Million USD | 3.35% |
| 2020 FY | 2.71 Billion USD | 130.43% |
| 2020 Q3 | 667.43 Million USD | -20.28% |
| 2020 Q4 | 604.19 Million USD | -9.48% |
| 2019 FY | 1.17 Billion USD | -43.88% |
| 2019 Q3 | 57.51 Million USD | -78.49% |
| 2019 Q2 | 267.42 Million USD | -0.45% |
| 2019 Q4 | 583.23 Million USD | 914.0% |
| 2019 Q1 | 268.63 Million USD | -82.67% |
| 2018 Q1 | 210.26 Million USD | 108.83% |
| 2018 Q2 | 207.36 Million USD | -1.38% |
| 2018 Q3 | 128.74 Million USD | -37.91% |
| 2018 FY | 2.09 Billion USD | 695.83% |
| 2018 Q4 | 1.55 Billion USD | 1104.33% |
| 2017 Q4 | 100.68 Million USD | 197.8% |
| 2017 Q1 | 247.75 Million USD | 652.03% |
| 2017 Q2 | 17.99 Million USD | -92.74% |
| 2017 FY | 263.48 Million USD | 335.14% |
| 2017 Q3 | -102.95 Million USD | -672.08% |
| 2016 Q2 | -64.52 Million USD | -54.99% |
| 2016 FY | -112.05 Million USD | 79.92% |
| 2016 Q4 | 32.94 Million USD | 178.74% |
| 2016 Q3 | -41.84 Million USD | 35.16% |
| 2016 Q1 | -41.63 Million USD | 44.87% |
| 2015 Q2 | -188.84 Million USD | 4.91% |
| 2015 Q4 | -75.51 Million USD | 20.64% |
| 2015 FY | -558.11 Million USD | 24.43% |
| 2015 Q3 | -95.14 Million USD | 49.62% |
| 2015 Q1 | -198.6 Million USD | -12.43% |
| 2014 Q4 | -176.65 Million USD | -3.88% |
| 2014 FY | -738.55 Million USD | -65.96% |
| 2014 Q2 | -159.38 Million USD | 31.44% |
| 2014 Q1 | -232.45 Million USD | -624.91% |
| 2014 Q3 | -170.06 Million USD | -6.7% |
| 2013 Q1 | -308.01 Million USD | -304.5% |
| 2013 FY | -445.02 Million USD | -315.79% |
| 2013 Q4 | 44.28 Million USD | 135.68% |
| 2013 Q2 | -57.16 Million USD | 81.44% |
| 2013 Q3 | -124.12 Million USD | -117.13% |
| 2012 Q1 | 91.59 Million USD | -42.26% |
| 2012 Q2 | -64.93 Million USD | -170.89% |
| 2012 FY | -107.03 Million USD | -461.91% |
| 2012 Q3 | -57.54 Million USD | 11.38% |
| 2012 Q4 | -76.14 Million USD | -32.33% |
| 2011 Q2 | -174.06 Million USD | 1.15% |
| 2011 Q3 | 221.11 Million USD | 227.02% |
| 2011 Q4 | 158.62 Million USD | -28.26% |
| 2011 FY | 29.57 Million USD | 103.92% |
| 2011 Q1 | -176.09 Million USD | 2.38% |
| 2010 Q2 | -200 Million USD | -21.02% |
| 2010 Q3 | -208.95 Million USD | -4.48% |
| 2010 FY | -754.62 Million USD | -17.62% |
| 2010 Q4 | -180.39 Million USD | 13.67% |
| 2010 Q1 | -165.27 Million USD | -4.18% |
| 2009 Q1 | -162.67 Million USD | -14.29% |
| 2009 Q3 | -149.56 Million USD | 12.69% |
| 2009 Q2 | -171.29 Million USD | -5.3% |
| 2009 FY | -641.57 Million USD | -39.52% |
| 2009 Q4 | -158.64 Million USD | -6.07% |
| 2008 FY | -459.85 Million USD | -17.53% |
| 2008 Q4 | -142.33 Million USD | -9.45% |
| 2008 Q3 | -130.04 Million USD | -42.4% |
| 2008 Q2 | -91.32 Million USD | 5.03% |
| 2008 Q1 | -96.15 Million USD | -12.13% |
| 2007 FY | -391.27 Million USD | -89.12% |
| 2007 Q2 | -117.76 Million USD | -45.88% |
| 2007 Q4 | -85.75 Million USD | 19.88% |
| 2007 Q3 | -107.03 Million USD | 9.11% |
| 2007 Q1 | -80.72 Million USD | -195.23% |
| 2006 FY | -206.89 Million USD | -1.71% |
| 2006 Q1 | -50.08 Million USD | -31.36% |
| 2006 Q4 | -27.34 Million USD | 47.21% |
| 2006 Q3 | -51.8 Million USD | 33.29% |
| 2006 Q2 | -77.65 Million USD | -55.05% |
| 2005 FY | -203.41 Million USD | -22.36% |
| 2005 Q4 | -38.13 Million USD | 52.08% |
| 2005 Q3 | -79.57 Million USD | -94.15% |
| 2005 Q2 | -40.98 Million USD | 8.35% |
| 2005 Q1 | -44.72 Million USD | -4.56% |
| 2004 FY | -166.24 Million USD | 15.51% |
| 2004 Q3 | -38.77 Million USD | 12.42% |
| 2004 Q1 | -40.43 Million USD | 1.44% |
| 2004 Q4 | -42.76 Million USD | -10.31% |
| 2004 Q2 | -44.26 Million USD | -9.47% |
| 2003 Q3 | -86.42 Million USD | -88.7% |
| 2003 Q2 | -45.79 Million USD | -322.2% |
| 2003 Q4 | -41.02 Million USD | 52.52% |
| 2003 FY | -196.76 Million USD | -81.15% |
| 2003 Q1 | 20.61 Million USD | 164.24% |
| 2002 Q1 | -22.06 Million USD | -576.9% |
| 2002 Q2 | -21.01 Million USD | 4.75% |
| 2002 FY | -108.62 Million USD | -64.0% |
| 2002 Q3 | -33.45 Million USD | -59.15% |
| 2002 Q4 | -32.08 Million USD | 4.09% |
| 2001 Q2 | -12.1 Million USD | -36.49% |
| 2001 Q1 | -8.87 Million USD | 21.18% |
| 2001 FY | -66.23 Million USD | -67.01% |
| 2001 Q4 | -3.26 Million USD | 93.06% |
| 2001 Q3 | -46.97 Million USD | -288.02% |
| 2000 Q1 | -16.15 Million USD | -1050.53% |
| 2000 FY | -39.65 Million USD | 3.27% |
| 2000 Q4 | -11.25 Million USD | 54.73% |
| 2000 Q3 | -24.85 Million USD | -297.08% |
| 2000 Q2 | 12.61 Million USD | 178.06% |
| 1999 Q2 | -10.8 Million USD | 38.64% |
| 1999 Q3 | -14.3 Million USD | -32.41% |
| 1999 Q4 | 1.7 Million USD | 111.89% |
| 1999 FY | -41 Million USD | -23.87% |
| 1999 Q1 | -17.6 Million USD | -39.68% |
| 1998 Q2 | -9.8 Million USD | -16.67% |
| 1998 FY | -33.1 Million USD | -67.17% |
| 1998 Q1 | -8.4 Million USD | -23.53% |
| 1998 Q3 | -2.3 Million USD | 76.53% |
| 1998 Q4 | -12.6 Million USD | -447.83% |
| 1997 Q1 | -5.8 Million USD | -48.72% |
| 1997 Q2 | -1.4 Million USD | 75.86% |
| 1997 FY | -19.8 Million USD | 50.5% |
| 1997 Q4 | -6.8 Million USD | -15.25% |
| 1997 Q3 | -5.9 Million USD | -321.43% |
| 1996 FY | -40 Million USD | -86.05% |
| 1996 Q3 | -6.3 Million USD | 71.75% |
| 1996 Q2 | -22.3 Million USD | -197.33% |
| 1996 Q4 | -3.9 Million USD | 38.1% |
| 1996 Q1 | -7.5 Million USD | -837.5% |
| 1995 Q1 | -4.7 Million USD | 4.08% |
| 1995 Q4 | -800 Thousand USD | 88.41% |
| 1995 Q3 | -6.9 Million USD | 23.33% |
| 1995 Q2 | -9 Million USD | -91.49% |
| 1995 FY | -21.5 Million USD | -22.16% |
| 1994 Q3 | -3.9 Million USD | 29.09% |
| 1994 FY | -17.6 Million USD | -980.0% |
| 1994 Q1 | -3.2 Million USD | -136.78% |
| 1994 Q2 | -5.5 Million USD | -71.88% |
| 1994 Q4 | -4.9 Million USD | -25.64% |
| 1993 Q4 | 8.7 Million USD | 422.22% |
| 1993 FY | 2 Million USD | 123.53% |
| 1993 Q1 | -3.3 Million USD | -22.22% |
| 1993 Q2 | -800 Thousand USD | 75.76% |
| 1993 Q3 | -2.7 Million USD | -237.5% |
| 1992 Q4 | -2.7 Million USD | -22.73% |
| 1992 Q2 | -1.9 Million USD | -18.75% |
| 1992 FY | -8.5 Million USD | -66.67% |
| 1992 Q1 | -1.6 Million USD | -23.08% |
| 1992 Q3 | -2.2 Million USD | -15.79% |
| 1991 FY | -5.1 Million USD | -18.6% |
| 1991 Q1 | - USD | 0.0% |
| 1991 Q3 | -1.2 Million USD | 14.29% |
| 1991 Q2 | -1.4 Million USD | 0.0% |
| 1991 Q4 | -1.3 Million USD | -8.33% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 FY | -4.3 Million USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 2572.438% |
| Alkermes plc | 355.75 Million USD | -917.436% |
| Agenus Inc. | -245.76 Million USD | 1572.813% |
| Aptorum Group Limited | -2.82 Million USD | 128243.446% |
| Ardelyx, Inc. | -66.06 Million USD | 5578.681% |
| Dyadic International, Inc. | -6.79 Million USD | 53364.966% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 386809.402% |
| Lantern Pharma Inc. | -15.96 Million USD | 22777.018% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 19121.61% |
| Novavax, Inc. | -545.06 Million USD | 764.071% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 6309.322% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 5005.272% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 19616.777% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 36346.745% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 6236.718% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 1068.766% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 14971.427% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 9793.626% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 2299.375% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 5034.898% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 17938.451% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 5914.151% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 11242.373% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 2831.918% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 922.184% |
| AlloVir, Inc. | -190.41 Million USD | 2000.871% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 1863.293% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 12821.777% |
| Bicycle Therapeutics plc | -180.66 Million USD | 2103.498% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 2121.524% |
| ChromaDex Corporation | -4.93 Million USD | 73400.932% |
| Chimerix, Inc. | -82.09 Million USD | 4509.038% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 8215.092% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 3646.194% |
| CRISPR Therapeutics AG | -153.61 Million USD | 2456.357% |
| Precision BioSciences, Inc. | -61.31 Million USD | 6002.901% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 2349.205% |
| Fortress Biotech, Inc. | -60.63 Million USD | 6069.293% |
| Fortress Biotech, Inc. | -60.63 Million USD | 6069.293% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 4536.872% |
| ImmuCell Corporation | -5.77 Million USD | 62781.42% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 3304.292% |
| Immix Biopharma, Inc. | -15.42 Million USD | 23564.208% |
| Incyte Corporation | 597.59 Million USD | -505.69% |
| Innoviva, Inc. | 179.72 Million USD | -1913.999% |
| IO Biotech, Inc. | -86.08 Million USD | 4304.779% |
| Jaguar Health, Inc. | -41.3 Million USD | 8864.165% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 2465.875% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -6840.216% |
| ContextLogic Inc. | -317 Million USD | 1241.83% |
| MiMedx Group, Inc. | 67.43 Million USD | -5267.221% |
| MEI Pharma, Inc. | 17.77 Million USD | -20259.996% |
| NextCure, Inc. | -62.72 Million USD | 5870.77% |
| Onconetix, Inc. | -37.4 Million USD | 9775.567% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 9268.419% |
| Opthea Limited | -220.24 Million USD | 1743.464% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 7175.19% |
| Vaxcyte, Inc. | -402.26 Million USD | 999.803% |
| PDS Biotechnology Corporation | -42.94 Million USD | 8529.005% |
| Precigen, Inc. | -95.9 Million USD | 3874.191% |
| Pharming Group N.V. | -10.54 Million USD | 34415.51% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 1895.508% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 14847.993% |
| PureTech Health plc | -65.69 Million USD | 5609.536% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 14525.89% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 1805.589% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 14971.427% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 1503.865% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 13388.788% |
| Acelyrin, Inc. | -381.64 Million USD | 1048.431% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 28858343.327% |
| Summit Therapeutics Inc. | -614.92 Million USD | 688.622% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 10714.351% |
| Senti Biosciences, Inc. | -92.91 Million USD | 3995.436% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 3557.149% |
| Elevation Oncology, Inc. | -45.7 Million USD | 8019.657% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 10400.512% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 27790.007% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 54245.101% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 12427.498% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 42678.52% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 6393.534% |
| Seer, Inc. | -86.27 Million USD | 4295.324% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 5502.791% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 5603.839% |
| ESSA Pharma Inc. | -26.58 Million USD | 13716.557% |
| GlycoMimetics, Inc. | -36.89 Million USD | 9909.368% |
| GT Biopharma, Inc. | -7.59 Million USD | 47745.123% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 1599.662% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 7070.823% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -4968.758% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 6750.987% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 7468.893% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 36486.132% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 731.866% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 100980.713% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 7189.193% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 1573.809% |
| Aptose Biosciences Inc. | -51.2 Million USD | 7168.565% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 3782.274% |
| Soligenix, Inc. | -6.14 Million USD | 59044.132% |
| Century Therapeutics, Inc. | -136.67 Million USD | 2748.365% |
| Kura Oncology, Inc. | -152.63 Million USD | 2471.471% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 4157.029% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 34448.074% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -640004.692% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 636233.568% |
| Autolus Therapeutics plc | -208.38 Million USD | 1836.994% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 5134.354% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 5212.79% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 16804.818% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 1706.926% |
| GRI Bio, Inc. | -13.03 Million USD | 27864.056% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 87644.606% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 3017.056% |
| IGM Biosciences, Inc. | -246.41 Million USD | 1568.898% |
| INmune Bio, Inc. | -30 Million USD | 12162.117% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 3373.908% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 8678.514% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 22776.842% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 23016.137% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 6164.505% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 3677.847% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 1410.851% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 1621.531% |
| Verastem, Inc. | -87.36 Million USD | 4242.983% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 6779.708% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 2343.517% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 3202.745% |
| Histogen Inc. | -10.62 Million USD | 34179.654% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 25435.353% |
| Surrozen, Inc. | -43.04 Million USD | 8509.461% |
| Organovo Holdings, Inc. | -14.67 Million USD | 24771.802% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 71253.516% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 7015.69% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 14427.673% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 13536.781% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 43411.748% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 2495.737% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 7498.105% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 12276.955% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 34844.7% |
| Apollomics, Inc. | -172.6 Million USD | 2197.091% |
| Amarin Corporation plc | -59.11 Million USD | 6223.291% |
| Mesoblast Limited | -87.95 Million USD | 4215.239% |
| Turnstone Biologics Corp. | -55.2 Million USD | 6657.246% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 2562.95% |
| Synaptogenix, Inc. | -6.03 Million USD | 60041.999% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 22432.182% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 4739.323% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 75642.642% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 43179.214% |
| Exelixis, Inc. | 207.76 Million USD | -1642.161% |
| Better Therapeutics, Inc. | -39.76 Million USD | 9203.622% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 2614.519% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 784.716% |
| NLS Pharmaceutics AG | -12.17 Million USD | 29837.031% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 46536.741% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 11871.44% |
| Gritstone bio, Inc. | -138.49 Million USD | 2713.618% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 5714.83% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 90591.131% |
| Avid Bioservices, Inc. | -140.75 Million USD | 2671.597% |
| Insmed Incorporated | -749.56 Million USD | 582.892% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 23929.607% |
| MediWound Ltd. | -6.71 Million USD | 53995.176% |
| OmniAb, Inc. | -50.61 Million USD | 7250.675% |
| Alector, Inc. | -130.39 Million USD | 2875.958% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 3282.793% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 7081.31% |
| Zai Lab Limited | -334.62 Million USD | 1181.705% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 1217.209% |
| Aura Biosciences, Inc. | -76.4 Million USD | 4837.2% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 1642.671% |
| Immunic, Inc. | -93.61 Million USD | 3966.598% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 2763.566% |
| Veracyte, Inc. | -74.4 Million USD | 4964.792% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 47257.533% |
| FibroGen, Inc. | -284.23 Million USD | 1373.467% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 13898.414% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 51794.614% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 19319.767% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | -772.546% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 16147.883% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -7246.309% |
| TG Therapeutics, Inc. | 12.67 Million USD | -28463.763% |
| Galecto, Inc. | -38.34 Million USD | 9538.577% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 19285.837% |
| Fortrea Holdings Inc. | -3.4 Million USD | 106558.824% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 2958.09% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 20889.156% |
| XBiotech Inc. | -24.55 Million USD | 14839.585% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 5714.83% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 5874.729% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 3777.484% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 16992.705% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 6658.078% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 696.665% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 5403.055% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 6357636.797% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 1697.782% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 16355.066% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 1747.444% |
| NexImmune, Inc. | -32.34 Million USD | 11290.812% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 68567.783% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 25869.807% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 8.448% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 15044.057% |
| Scopus BioPharma Inc. | -11.6 Million USD | 31277.036% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 3199.026% |
| Ainos, Inc. | -13.77 Million USD | 26385.081% |
| Pluri Inc. | -20.88 Million USD | 17428.61% |
| Prothena Corporation plc | -147.02 Million USD | 2561.844% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 3278.685% |
| Celularity Inc. | -196.29 Million USD | 1943.959% |
| Rallybio Corporation | -74.56 Million USD | 4954.353% |
| Cue Biopharma, Inc. | -50.73 Million USD | 7234.607% |
| MeiraGTx Holdings plc | -84.02 Million USD | 4407.663% |
| Omeros Corporation | -117.81 Million USD | 3172.326% |
| Humacyte, Inc. | -110.77 Million USD | 3367.495% |
| Immunocore Holdings plc | -55.28 Million USD | 6646.928% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 20226.779% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 15884.746% |
| Blueprint Medicines Corporation | -506.98 Million USD | 813.948% |
| CalciMedica, Inc. | -34.35 Million USD | 10635.262% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 5448.504% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 2659.74% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 2283.257% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 1377.859% |
| Pulmatrix, Inc. | -14.12 Million USD | 25732.746% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 10384.415% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 4480.067% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 852.215% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 3551.478% |
| Cytokinetics, Incorporated | -526.24 Million USD | 787.818% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 10136.323% |
| Nutriband Inc. | -5.48 Million USD | 66087.107% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 9054.973% |
| Vor Biopharma Inc. | -117.86 Million USD | 3171.023% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 16.77% |
| Evogene Ltd. | -23.87 Million USD | 15258.089% |
| ProKidney Corp. | -35.46 Million USD | 10305.255% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 3122.302% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 46236.648% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 662.747% |
| CorMedix Inc. | -46.33 Million USD | 7911.093% |
| BioLineRx Ltd. | -60.61 Million USD | 6071.558% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 3657.556% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 8914.104% |
| Atai Life Sciences N.V. | -40.22 Million USD | 9098.608% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 4588.025% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 4892.839% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 1338.779% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 13084.646% |
| MediciNova, Inc. | -8.57 Million USD | 42328.236% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 3036.152% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 43309.642% |
| GeoVax Labs, Inc. | -25.96 Million USD | 14039.358% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 1612.97% |
| Biomea Fusion, Inc. | -117.25 Million USD | 3186.947% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 677.654% |
| Mereo BioPharma Group plc | -29.46 Million USD | 12383.988% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 2463.249% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 1828.888% |
| Absci Corporation | -110.56 Million USD | 3373.701% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 12105.307% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 3689.555% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 1634.138% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -25600.085% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 1975.81% |
| Allakos Inc. | -185.7 Million USD | 2049.155% |
| Imunon, Inc. | -19.51 Million USD | 18647.806% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 3818.703% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -3310.213% |
| BioAtla, Inc. | -123.46 Million USD | 3031.752% |
| NLS Pharmaceutics AG | -12.17 Million USD | 29837.031% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 22612.75% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 1206.015% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 9896.206% |
| XOMA Corporation | -40.83 Million USD | 8964.833% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 3653.156% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 3154.18% |
| aTyr Pharma, Inc. | -50.38 Million USD | 7283.314% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 4228.241% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 2485.097% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 1622.542% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 10406.672% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 44830.93% |
| Akari Therapeutics, Plc | -10 Million USD | 36267.066% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 5376408.949% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -1185.397% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 54408.4% |
| UroGen Pharma Ltd. | -102.24 Million USD | 3640.159% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 3489.361% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 46641.267% |
| Orgenesis Inc. | -55.36 Million USD | 6638.177% |
| Entera Bio Ltd. | -8.88 Million USD | 40819.991% |
| GH Research PLC | -35.58 Million USD | 10271.13% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 17468.522% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 4777.211% |
| Xencor, Inc. | -126.08 Million USD | 2970.716% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 96220.192% |
| Replimune Group, Inc. | -215.79 Million USD | 1777.34% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 17120.166% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -144164.647% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 54408.4% |
| Portage Biotech Inc. | -75.33 Million USD | 4904.417% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 43309.642% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 3844.866% |
| OncoCyte Corporation | -27.78 Million USD | 13129.049% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 27077.289% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 32645.911% |
| Purple Biotech Ltd. | -19.88 Million USD | 18307.243% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 51668.6% |
| scPharmaceuticals Inc. | -54.81 Million USD | 6703.904% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 20776.172% |
| HilleVax, Inc. | -123.56 Million USD | 3029.285% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 35912.803% |
| Tharimmune, Inc. | -9.31 Million USD | 38940.686% |
| Genprex, Inc. | -30.86 Million USD | 11828.924% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 1634.216% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 12127.647% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 203220.09% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 68445.728% |
| OKYO Pharma Limited | -16.82 Thousand USD | 21512736.207% |
| Savara Inc. | -54.69 Million USD | 6717.427% |
| Curis, Inc. | -47.41 Million USD | 7734.193% |
| Daré Bioscience, Inc. | -30.16 Million USD | 12100.773% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 23535.284% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 65095.511% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 12240.198% |
| BeiGene, Ltd. | -881.7 Million USD | 510.521% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 17098.215% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 929.485% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 4684.384% |
| Erasca, Inc. | -125.04 Million USD | 2994.707% |
| bluebird bio, Inc. | -211.91 Million USD | 1808.059% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 72484.805% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -2059.086% |
| DBV Technologies S.A. | -72.72 Million USD | 5077.037% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 72484.805% |
| Moderna, Inc. | -4.71 Billion USD | 176.784% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 9113.622% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 63668.669% |
| Molecular Templates, Inc. | -8.12 Million USD | 44654.407% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 6093.906% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 3349.221% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 2774.212% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 7653.58% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 2659.305% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 1981.191% |
| MacroGenics, Inc. | -9.05 Million USD | 40060.256% |
| RenovoRx, Inc. | -10.23 Million USD | 35475.293% |
| Adicet Bio, Inc. | -142.65 Million USD | 2637.257% |
| Prime Medicine, Inc. | -198.13 Million USD | 1926.854% |
| Aditxt, Inc. | -32.38 Million USD | 11278.216% |
| Adagene Inc. | -18.94 Million USD | 19204.451% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 49604.064% |
| Quantum-Si incorporated | -95.96 Million USD | 3871.988% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 3140.94% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 24929.59% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -2635.283% |
| SciSparc Ltd. | -5.12 Million USD | 70767.708% |
| Vericel Corporation | -3.18 Million USD | 113852.357% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 3010062.247% |
| Minerva Neurosciences, Inc. | -30 Million USD | 12163.181% |
| Generation Bio Co. | -126.61 Million USD | 2958.813% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 5065.771% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 4490.481% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 1480.789% |
| Invivyd, Inc. | -198.64 Million USD | 1922.163% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 1158.446% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 41768.907% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -15771.262% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 36757.889% |
| 2seventy bio, Inc. | -217.57 Million USD | 1763.648% |
| ADMA Biologics, Inc. | -28.23 Million USD | 12917.734% |
| Clene Inc. | -49.5 Million USD | 7411.732% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 16340.463% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 7422.086% |
| GeoVax Labs, Inc. | -25.96 Million USD | 14039.358% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 1203.315% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 11222.545% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -15831.338% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 3763.869% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 4942.015% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 2350.925% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 688.494% |
| Evaxion Biotech A/S | -22.12 Million USD | 16459.774% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 4583.254% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 1909.185% |
| Trevena, Inc. | -40.28 Million USD | 9084.09% |
| Surrozen, Inc. | -43.04 Million USD | 8509.461% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 5335.629% |
| Cingulate Inc. | -23.53 Million USD | 15479.682% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 52466.898% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 9180.783% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 47042.725% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 4112.415% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 6006.08% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 6183.055% |
| Clearmind Medicine Inc. | -11.95 Million USD | 30376.793% |
| Kronos Bio, Inc. | -112.67 Million USD | 3312.482% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 5330.863% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 142715863.16% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 4313.982% |
| Statera Biopharma, Inc. | -174.4 Million USD | 2175.362% |
| ImmunityBio, Inc. | -583.19 Million USD | 720.649% |
| Korro Bio, Inc. | -81.17 Million USD | 4559.173% |
| Kineta, Inc. | -14.09 Million USD | 25772.743% |
| BioVie Inc. | -32.12 Million USD | 11368.804% |
| Codexis, Inc. | -76.24 Million USD | 4847.639% |
| Celularity Inc. | -196.29 Million USD | 1943.959% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 1787.231% |
| Celcuity Inc. | -63.77 Million USD | 5775.212% |
| Virax Biolabs Group Limited | -6.73 Million USD | 53854.81% |
| Cibus, Inc. | -267.62 Million USD | 1452.479% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 9075.847% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 10207.509% |
| IN8bio, Inc. | -30 Million USD | 12162.519% |
| Kodiak Sciences Inc. | -260.49 Million USD | 1489.53% |
| Annexon, Inc. | -134.23 Million USD | 2796.425% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 3189.318% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 6011.674% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 11574.765% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 1088.19% |
| Eyenovia, Inc. | -27.26 Million USD | 13377.529% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -16664.393% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 676660.748% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 4837.448% |
| Arcellx, Inc. | -70.69 Million USD | 5220.385% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 8834.345% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 2804.908% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 12150.471% |
| Moolec Science SA | -51.78 Million USD | 7089.145% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 7011.459% |
| Geron Corporation | -184.12 Million USD | 2065.817% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 8723.434% |
| Royalty Pharma plc | 1.13 Billion USD | -218.954% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 2762.332% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 40807.155% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 17138.839% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 2208.464% |
| Humacyte, Inc. | -110.77 Million USD | 3367.495% |
| Structure Therapeutics Inc. | -89.62 Million USD | 4138.831% |
| 89bio, Inc. | -142.18 Million USD | 2645.626% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 5348.84% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 34980.987% |
| Genelux Corporation | -28.29 Million USD | 12891.462% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 12553.466% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 2143.598% |
| Notable Labs, Ltd. | -11.26 Million USD | 32234.233% |
| Liquidia Corporation | -78.5 Million USD | 4710.838% |
| Mustang Bio, Inc. | -51.6 Million USD | 7114.457% |
| Immunovant, Inc. | -259.33 Million USD | 1495.718% |
| Quantum-Si incorporated | -95.96 Million USD | 3871.988% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 5068.634% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 18776.023% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 3870.809% |
| Acasti Pharma Inc. | -12.85 Million USD | 28261.519% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 16217.298% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 22776.842% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 2084.506% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 84247.058% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 29126.464% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 12373.575% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 9383.882% |
| PepGen Inc. | -78.62 Million USD | 4703.566% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 12258.957% |
| United Therapeutics Corporation | 984.8 Million USD | -267.547% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 16360.557% |
| Solid Biosciences Inc. | -96.01 Million USD | 3869.828% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 75642.642% |
| Immuneering Corporation | -53.47 Million USD | 6869.198% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 71253.516% |
| Silo Pharma, Inc. | -3.7 Million USD | 97908.972% |
| Belite Bio, Inc | -31.63 Million USD | 11542.843% |
| XOMA Corporation | -40.83 Million USD | 8964.833% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 6757.96% |
| Bionomics Limited | -15.49 Billion USD | 123.364% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 4409.817% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 12514.172% |
| uniQure N.V. | -308.47 Million USD | 1273.374% |
| Cassava Sciences, Inc. | -97.21 Million USD | 3823.217% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 49604.064% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 3032.512% |
| Forte Biosciences, Inc. | -31.47 Million USD | 11599.555% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 44232.298% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 12552.181% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 676660.748% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 13898.414% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 22056.931% |
| Altimmune, Inc. | -88.44 Million USD | 4192.394% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 2487.851% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 12514.172% |
| Compugen Ltd. | -18.75 Million USD | 19400.416% |
| Peak Bio, Inc. | -1259.26 USD | 287438754.448% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 7960.323% |
| Benitec Biopharma Inc. | -21.75 Million USD | 16741.074% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 1168.39% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 4463.382% |
| Zura Bio Limited | -60.36 Million USD | 6096.687% |
| PolyPid Ltd. | -23.86 Million USD | 15266.981% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 23107.882% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 4463.382% |
| Instil Bio, Inc. | -156.08 Million USD | 2418.963% |
| argenx SE | -295.05 Million USD | 1326.763% |
| Immunome, Inc. | -106.8 Million USD | 3488.948% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 8617.908% |
| Verona Pharma plc | -54.36 Million USD | 6757.47% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 3722.607% |
| Shattuck Labs, Inc. | -87.29 Million USD | 4246.258% |
| CervoMed Inc. | -2.17 Million USD | 166757.995% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 3003.787% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 27282.337% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 8410.412% |
| Moolec Science SA | -51.78 Million USD | 7089.145% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 20932649.837% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 2778.857% |
| AnaptysBio, Inc. | -163.61 Million USD | 2312.213% |
| Design Therapeutics, Inc. | -66.86 Million USD | 5513.538% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 4545.918% |
| NeurAxis, Inc. | -14.62 Million USD | 24846.554% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 9654.934% |
| Lumos Pharma, Inc. | -34.03 Million USD | 10735.247% |
| Achilles Therapeutics plc | -69.66 Million USD | 5295.722% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 3722.607% |
| 180 Life Sciences Corp. | -19.93 Million USD | 18256.908% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -120200.852% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 142715863.16% |
| Nutriband Inc. | -5.48 Million USD | 66087.107% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 3694.546% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 7546.664% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 4795.23% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 10755.284% |
| MoonLake Immunotherapeutics | -36 Million USD | 10152.417% |
| Palisade Bio, Inc. | -12.3 Million USD | 29527.642% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 8692.726% |
| Beam Therapeutics Inc. | -132.52 Million USD | 2831.217% |
| Neurogene Inc. | -36.31 Million USD | 10066.682% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 2314.974% |
| AEON Biopharma, Inc. | -52.55 Million USD | 6987.13% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 3787.937% |
| Sesen Bio, Inc. | -19.88 Million USD | 18303.581% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 5156.437% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 29024.645% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 915.157% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 3344.358% |
| Athira Pharma, Inc. | -117.67 Million USD | 3176.008% |
| Vaccinex, Inc. | -20.25 Million USD | 17973.685% |
| HCW Biologics Inc. | -24.99 Million USD | 14581.715% |
| XOMA Corporation | -40.83 Million USD | 8964.833% |
| Nektar Therapeutics | -276.05 Million USD | 1411.183% |
| Arvinas, Inc. | -367.3 Million USD | 1085.461% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 5376408.949% |
| Merus N.V. | -154.93 Million USD | 2436.145% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 3815.154% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 11632.898% |
| Rezolute, Inc. | -68.45 Million USD | 5387.252% |
| Clene Inc. | -49.5 Million USD | 7411.732% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 23568.129% |
| BeyondSpring Inc. | -21.02 Million USD | 17314.877% |
| Synlogic, Inc. | -57.28 Million USD | 6418.913% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 30514.251% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 33534.325% |
| Peak Bio, Inc. | -1259.26 USD | 287438754.448% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 9786.363% |
| Krystal Biotech, Inc. | 10.93 Million USD | -33010.135% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 2629.438% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 1213.367% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 78463.876% |
| MannKind Corporation | -11.93 Million USD | 30419.987% |
| Ikena Oncology, Inc. | -68.16 Million USD | 5409.979% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 17323.888% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 3994.849% |
| Gossamer Bio, Inc. | -179.81 Million USD | 2112.935% |
| CohBar, Inc. | -11.96 Million USD | 30358.853% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 14135.986% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 12105.307% |
| Legend Biotech Corporation | -518.25 Million USD | 798.422% |
| Mural Oncology plc | -207.44 Million USD | 1844.831% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 3016.328% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 19890.347% |
| Disc Medicine, Inc. | -76.42 Million USD | 4835.899% |
| Champions Oncology, Inc. | -7.27 Million USD | 49847.114% |
| REGENXBIO Inc. | -263.49 Million USD | 1473.694% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 34205.105% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 7719.408% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 9629.402% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 3713.71% |
| Vaxart, Inc. | -82.46 Million USD | 4489.256% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -1084382.103% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 9741.337% |
| Cellectis S.A. | -101.05 Million USD | 3681.67% |
| Longeveron Inc. | -21.41 Million USD | 17003.75% |
| Repare Therapeutics Inc. | -93.79 Million USD | 3959.013% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 775.327% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 5185.922% |
| Revolution Medicines, Inc. | -436.36 Million USD | 929.485% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 55184.462% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 11842.798% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 5320.602% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 5691.67% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 36993.283% |
| Denali Therapeutics Inc. | -145.22 Million USD | 2592.425% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 3010062.247% |
| Veru Inc. | -93.15 Million USD | 3985.663% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 13491.542% |
| Cingulate Inc. | -23.53 Million USD | 15479.682% |
| Passage Bio, Inc. | -102.06 Million USD | 3646.472% |
| Context Therapeutics Inc. | -23.96 Million USD | 15204.19% |
| Exicure, Inc. | -16.91 Million USD | 21500.024% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 2015.974% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 9684.79% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 55723.475% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 2059.952% |
| Nuvalent, Inc. | -126.21 Million USD | 2967.714% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 34521.058% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 4266.254% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 11950.445% |
| OmniAb, Inc. | -50.61 Million USD | 7250.675% |
| Anew Medical, Inc. | 1.34 Million USD | -268790.333% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 22659.053% |
| Lipocine Inc. | -16.35 Million USD | 22235.408% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 5551.697% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 5784.492% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 8678.514% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 7646.021% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 18352.231% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 768.453% |
| Ocugen, Inc. | -63.07 Million USD | 5838.292% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 3880.972% |
| Q32 Bio Inc. | -112.96 Million USD | 3304.292% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 21153.979% |
| Alumis Inc. Common Stock | -154.99 Million USD | 2435.331% |
| Equillium, Inc. | -13.33 Million USD | 27243.607% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 6096.091% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 45413.9% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 19300.873% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 6226.401% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 3260.477% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 19795.337% |
| Dominari Holdings Inc. | -22.88 Million USD | 15918.547% |
| Edesa Biotech, Inc. | -8.37 Million USD | 43322.124% |
| vTv Therapeutics Inc. | -20.25 Million USD | 17974.568% |
| Bio-Techne Corporation | 168.1 Million USD | -2053.178% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 1128.038% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -2709.093% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 3070.976% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 9640.578% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 3313.366% |
| Nkarta, Inc. | -117.5 Million USD | 3180.484% |
| BioCardia, Inc. | -11.57 Million USD | 31381.652% |
| Iterum Therapeutics plc | -38.37 Million USD | 9533.166% |